Trial Profile
A randomized, double-blind, placebo-controlled study to investigate the safety, tolerability and efficacy of orally administered QAL964 in patients with active rheumatoid arthritis on stable doses of methotrexate and with inadequate response to methotrexate
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 May 2015
Price :
$35
*
At a glance
- Drugs QAL 964 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Novartis
- 16 May 2015 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 15 Apr 2014 New trial record